|
|
|
|
| LEADER |
01888nam a2200241 u 4500 |
| 001 |
EB002000969 |
| 003 |
EBX01000000000000001163870 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Gerrity, Martha
|
| 245 |
0 |
0 |
|a Roadmap for narratively describing effects of interventions in systematic reviews
|h Elektronische Ressource
|c investigators, Martha Gerrity [and 14 others]
|
| 260 |
|
|
|a Rockville, MD
|b Agency for Healthcare Research and Quality
|c 2020, November 2020
|
| 300 |
|
|
|a 1 PDF file (various pagings)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Scientific Resource Center (Portland, Or.)
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Methods white paper
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK563873
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Accurately describing treatment effects using plain language and narrative statements is a critical step in communicating research findings to end users. However, the process of developing these narratives has not been historically guided by a specific framework. The Agency for Healthcare Research and Quality Evidence-based Practice Center Program developed guidance for narrative summaries of treatment effects that identifies five constructs. We explicitly identify these constructs to facilitate developing narrative statements (1) size of effect, (2) direction of effect, (3) clinical importance, (4) statistical significance, and (5) strength or certainty of evidence. These constructs clearly overlap. It may not always be feasible to address all five constructs. Based on context and intended audience, investigators can assess which constructs will be most important to address in narrative statements
|